SG10201608136SA - Anti-hla-b*27 antibodies and uses thereof - Google Patents

Anti-hla-b*27 antibodies and uses thereof

Info

Publication number: SG10201608136SA
Authority: SG; Singapore
Prior art keywords: hla; antibodies
Prior art date: 2012-04-02

Application number

SG10201608136SA

Inventor

Andrew J Murphy

Ana Kostic

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-02

Filing date

2013-04-02

Publication date

2016-11-29

2013-04-02 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2016-11-29 Publication of SG10201608136SA publication Critical patent/SG10201608136SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SG10201608136SA 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof SG10201608136SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261618969P	2012-04-02	2012-04-02
US201361778703P	2013-03-13	2013-03-13

Publications (1)

Publication Number	Publication Date
SG10201608136SA true SG10201608136SA (en)	2016-11-29

Family

ID=48093122

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201405759UA SG11201405759UA (en)	2012-04-02	2013-04-02	Anti-hla-b*27 antibodies and uses thereof
SG10201608136SA SG10201608136SA (en)	2012-04-02	2013-04-02	Anti-hla-b*27 antibodies and uses thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201405759UA SG11201405759UA (en)	2012-04-02	2013-04-02	Anti-hla-b*27 antibodies and uses thereof

Country Status (22)

Country	Link
US (1)	US9790273B2 (en)
EP (1)	EP2834272B1 (en)
JP (1)	JP6320993B2 (en)
KR (1)	KR20150003256A (en)
CN (1)	CN104169302A (en)
AR (1)	AR090585A1 (en)
AU (1)	AU2013243644C1 (en)
BR (1)	BR112014024622A2 (en)
CA (1)	CA2868907C (en)
CL (1)	CL2014002631A1 (en)
CO (1)	CO7121320A2 (en)
EA (1)	EA201491827A1 (en)
HK (1)	HK1207092A1 (en)
IL (2)	IL234707A0 (en)
MX (1)	MX365690B (en)
MY (1)	MY171180A (en)
NZ (1)	NZ700650A (en)
PH (1)	PH12014502184A1 (en)
SG (2)	SG11201405759UA (en)
TW (1)	TWI619729B (en)
UY (1)	UY34721A (en)
WO (1)	WO2013152001A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2647846C (en)	2006-03-31	2016-06-21	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (en)	2007-09-26	2021-04-23	中外制药株式会社	Method for changing isoelectric point of antibody by using amino acid substitution of CDR
CA2721052C (en)	2008-04-11	2023-02-21	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BR112013013354A2 (en)	2010-11-30	2020-10-06	Chugai Seiyaku Kabushiki Kaisha	antigen-binding molecule capable of binding to a plurality of antigen molecules repeatedly
EP2679681B2 (en)	2011-02-25	2023-11-15	Chugai Seiyaku Kabushiki Kaisha	FcgammaRIIB-specific FC antibody
EP4011913A1 (en)	2011-06-30	2022-06-15	Chugai Seiyaku Kabushiki Kaisha	Heterodimerized polypeptide
JP6322411B2 (en)	2011-09-30	2018-05-09	中外製薬株式会社	Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
CN104080909A (en)	2011-11-30	2014-10-01	中外制药株式会社	A drug that contains a transporter (carrier) that enters cells to form immune complexes
TWI619729B (en)	2012-04-02	2018-04-01	再生元醫藥公司	Anti-hla-b*27 antibodies and uses thereof
CN116376983A (en)	2012-07-27	2023-07-04	希望之城	An MVA vaccine that delivers the UL128 complex and protects against CMV infection
JP6501521B2 (en)	2012-08-24	2019-04-17	中外製薬株式会社	FcγRIIb-specific Fc region variant
JP6774164B2 (en)	2012-08-24	2020-10-21	中外製薬株式会社	Mouse FcγRII specific Fc antibody
KR102249779B1 (en)	2012-12-27	2021-05-07	추가이 세이야쿠 가부시키가이샤	Heterodimerized polypeptide
CA2908350C (en)	2013-04-02	2023-08-08	Futa Mimoto	Fc region variant
TWI617580B (en) *	2014-12-19	2018-03-11	中外製藥股份有限公司	Anti-c5 antibodies and methods of use
MY181199A (en)	2014-12-19	2020-12-21	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3253407B1 (en) *	2015-02-04	2020-04-22	Universität Zürich	Use of hla-b27 homodimers for cancer treatment
CN107108729A (en)	2015-02-05	2017-08-29	中外制药株式会社	Antibody comprising ion concentration-dependent antigen-binding domain, FC region variant, IL-8-binding antibody, and application thereof
CA2977106A1 (en)	2015-02-27	2016-09-01	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US11173179B2 (en)	2015-06-25	2021-11-16	Icell Gene Therapeutics Llc	Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US11655452B2 (en)	2015-06-25	2023-05-23	Icell Gene Therapeutics Inc.	Chimeric antigen receptors (CARs), compositions and methods of use thereof
EP3341738A4 (en)	2015-08-24	2019-02-27	University of Cincinnati	METHODS AND COMPOSITIONS FOR DETECTION OF FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES
EP3347045A4 (en)	2015-09-10	2019-08-28	City of Hope	ANTIBODIES GENERATED BY MVA-GH / GL-PC VACCINE NEUTRALIZING THE INFECTIOUS POWER OF HUMAN CYTOMEGALOVIRUS AND ASSOCIATED METHODS
WO2017104783A1 (en) *	2015-12-18	2017-06-22	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL259256B2 (en) *	2015-12-18	2023-02-01	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
WO2017153438A1 (en)	2016-03-08	2017-09-14	Universität Zürich	Hla-b57 open conformers
JP7114490B2 (en)	2016-06-24	2022-08-08	アイセル・ジーン・セラピューティクス・エルエルシー	Construction of chimeric antibody receptors (CARs) and methods of their use
JP6527643B2 (en)	2016-08-05	2019-06-05	中外製薬株式会社	Composition for treating or preventing IL-8 related diseases
CA3031605A1 (en)	2016-08-10	2018-02-15	Universitat Zurich	Mhc class ia open conformers
US11608374B2 (en)	2017-01-30	2023-03-21	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
US20200114022A1 (en) *	2017-03-31	2020-04-16	Alma Bio Therapeutics	Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
JP2020524512A (en)	2017-06-21	2020-08-20	アイセル・ジーン・セラピューティクス・エルエルシー	Compositions of chimeric antibody receptors (CARs) and methods of use thereof
EP3710589A4 (en)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	ANTI-C1S ANTIBODIES AND METHODS OF USE
CN108486226B (en) *	2018-04-01	2022-04-12	广东辉锦创兴生物医学科技有限公司	HLA-B27 allele detection kit and application thereof
SG10202106830VA (en)	2018-08-10	2021-08-30	Chugai Pharmaceutical Co Ltd	Anti-cd137 antigen-binding molecule and utilization thereof
EP3941489A4 (en) *	2019-03-21	2022-12-28	Gamida-Cell Ltd.	EXPANDED NK CELL FRACTIONS FOR TRANSPLANTATION IN COMBINATION THERAPY
CA3137649A1 (en)	2019-05-15	2020-11-19	Chugai Seiyaku Kabushiki Kaisha	An antigen-binding molecule, a pharmaceutical composition, and a method
CN111175490A (en) *	2020-01-19	2020-05-19	泛肽生物科技(浙江)有限公司	Kit for qualitatively detecting HLA-B27 and detection method thereof
WO2022216832A1 (en) *	2021-04-07	2022-10-13	Regeneron Pharmaceuticals, Inc.	A composition for use in treating mhc-1-opathies
US12157891B2 (en) *	2021-10-14	2024-12-03	Regeneron Pharmaceuticals, Inc.	Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
WO2023220263A1 (en) *	2022-05-13	2023-11-16	Memorial Sloan-Kettering Cancer Center	Compositions and methods for modulating tcr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340610C (en) *	1985-08-16	1999-06-29	Karen A. Nelson	Monoclonal antibody to polymorphic hla determinant-b27
US5369010A (en)	1985-08-16	1994-11-29	Genetic Systems Corporation	Monoclonal antibody to polymorphic HLA determinant -B27
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
US5734023A (en) *	1991-11-19	1998-03-31	Anergen Inc.	MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
PL2374818T3 (en)	2006-06-02	2013-05-31	Regeneron Pharma	High affinity antibodies to human IL-6 receptor
US20130315933A1 (en)	2010-10-06	2013-11-28	Christoph Renner	Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
TWI619729B (en)	2012-04-02	2018-04-01	再生元醫藥公司	Anti-hla-b*27 antibodies and uses thereof

2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/en not_active IP Right Cessation
- 2013-04-02 EA EA201491827A patent/EA201491827A1/en unknown
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/en active Pending
- 2013-04-02 MX MX2014011898A patent/MX365690B/en active IP Right Grant
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/en active Active
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/en not_active Withdrawn
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/en not_active IP Right Cessation
- 2013-04-02 UY UY0001034721A patent/UY34721A/en not_active Application Discontinuation
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/en unknown
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-03 AR ARP130101081A patent/AR090585A1/en unknown
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/en unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/en unknown
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown

Also Published As

Publication number	Publication date
BR112014024622A2 (en)	2017-08-08
CA2868907C (en)	2022-01-04
WO2013152001A2 (en)	2013-10-10
US9790273B2 (en)	2017-10-17
UY34721A (en)	2013-10-31
IL234707A0 (en)	2014-11-30
PH12014502184A1 (en)	2014-12-10
US20130259876A1 (en)	2013-10-03
KR20150003256A (en)	2015-01-08
EA201491827A1 (en)	2015-03-31
MY171180A (en)	2019-09-30
EP2834272B1 (en)	2020-06-24
NZ700650A (en)	2017-02-24
EP2834272A2 (en)	2015-02-11
CL2014002631A1 (en)	2015-01-16
AU2013243644C1 (en)	2018-05-10
CA2868907A1 (en)	2013-10-10
JP6320993B2 (en)	2018-05-09
IL256716A (en)	2018-03-29
WO2013152001A3 (en)	2013-12-27
CO7121320A2 (en)	2014-11-20
AU2013243644B2 (en)	2018-02-08
AU2013243644A1 (en)	2014-10-23
TWI619729B (en)	2018-04-01
SG11201405759UA (en)	2014-11-27
MX365690B (en)	2019-06-11
CN104169302A (en)	2014-11-26
HK1207092A1 (en)	2016-01-22
TW201343675A (en)	2013-11-01
AR090585A1 (en)	2014-11-26
MX2014011898A (en)	2014-11-12
JP2015514110A (en)	2015-05-18

Publication	Publication Date	Title
IL256716A (en)	2018-03-29	Anti-hla-b*27 antibodies and uses thereof
IL235392B (en)	2019-02-28	Anti-egfr antibodies and uses thereof
IL254416A0 (en)	2017-11-30	Anti-asic1 antibodies and uses thereof
ZA201500457B (en)	2021-07-28	Anti-kit antibodies and uses thereof
EP2861622A4 (en)	2016-06-01	Anti-cd22 anti-idiotypic antibodies and uses thereof
IL233757A0 (en)	2014-09-30	Anti-ig-e m1' antibodies and methods using same
IL237287A0 (en)	2015-04-30	Antibody formulations and uses thereof
ZA201405554B (en)	2015-12-23	Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
ZA201408213B (en)	2020-02-26	Anti-transglutaminase 2 antibodies
SG11201504482VA (en)	2015-07-30	Beta-hexosyl-transferases and uses thereof
IL237400B (en)	2019-03-31	Rhizobacteria and uses thereof
GB201208372D0 (en)	2012-06-27	Antibodies and uses thereof